Why Marijuana Could Be Reclassified as a Safer Drug Soon
Marijuana federal rescheduling impact could transform clinical research and policy landscapes. This change may enable higher-quality trials and improved dosing studies. It represents a significant shift in cannabis regulation and medical use.
Quasi-randomization to Cannabinoid Condition in US Legal Market Cannabis Studies
Quasi-randomization cannabis research addresses challenges in legal market cannabis studies where true randomization is restricted. This method helps identify selection bias between accepters and decliners of cannabinoid condition assignments.…
US Representatives Introduce the Higher Education Marijuana Research Act – MMJDaily
Federal research barriers cannabis have created a decades-long evidence gap in medical studies. The Higher Education Marijuana Research Act aims to reduce these barriers. This legislation could accelerate clinical evidence generation for cannabis…
DOJ Expected to Ease Marijuana Controls as Soon as Wednesday
The DOJ marijuana controls easing is anticipated to reshape federal cannabis regulation. This change will facilitate expanded cannabis research and clinical trials. It marks a pivotal shift in marijuana policy impacting medical research.
How U.S. Marijuana Reclassification Could Help Cannabis Companies
Federal cannabis reclassification benefits cannabis companies by reducing regulatory barriers and enabling larger clinical trials. This shift could improve product quality and research funding. It marks a significant step toward evidence-based cannabis…
Explainer: How US Marijuana Reclassification Could Help Cannabis Companies
Marijuana reclassification benefits could reshape the cannabis industry by enabling more rigorous research and easing regulatory burdens. This shift may reduce taxes for cannabis companies and improve product quality. Patients could also gain better…
Marijuana MSOs Surge Amid 2026 Federal Reclassification Report
Marijuana federal reclassification 2026 could remove longstanding research barriers that have limited clinical trials. This shift may accelerate evidence generation for medical cannabis. Clinicians and patients should monitor these changes closely for…
Federal Bill Would Create Cannabis Research Protections – Ganjapreneur
Cannabis research protections are critical to overcoming federal scheduling conflicts that have limited scientific studies. This federal bill aims to reduce regulatory barriers and promote high-quality cannabis research. Improved protections could expand…
The Limits of Averages: A Framework for Contextual Effectiveness in Palliative Care Medicinal Cannabis Research.
This article explores contextual effectiveness in palliative care cannabis research, addressing why patient-reported benefits often differ from clinical trial averages. It highlights the importance of individualized treatment outcomes in medicinal…
Fund a Medical Cannabis Trial for Children Without NHS Access Since 2018
Pediatric medical cannabis trials are urgently needed to improve NHS access for children. Despite legalization in 2018, limited clinical evidence restricts treatment availability. Funding these trials will help establish safety and efficacy data for…